Additionally, ibrutinib demonstrated to improve the curative effects of CD19-directed CAR T cells in Raji cell subcutaneous tumorigenic mice, possibly thanks to its beneficial impact on the tumor microenvironment (87). This evidence concerns the gene CD19 and neoplasm.